Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

BioMed X launches groundbreaking AI-driven diabetes research in Barbados

With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial

Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit